There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TIGIT


TIGIT Molecule Information

Name:T cell immunoglobulin and ITIM domains
Target Synonym:VSTM3;V-set and transmembrane domain-containing protein 3;VSIG9;V-set and immunoglobulin domain-containing protein 9;TIGIT
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase ?

TIGIT Protein Product ListCompare or Buy

TIGIT Molecule Synonym Name


TIGIT Molecule Background

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is also known as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane domain-containing protein 3 (VSTM3),which belongs to single-pass type I membrane protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level). TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.

TIGIT References

TIGIT Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Tiragolumab MTIG-7192A; RG-6058; RO-7092284 Phase Ⅲ Roche Small cell lung cancer (SCLC) Details
AB-154 AB-154 Phase Ⅱ Arcus Biosciences Non small cell lung cancer (NSCLC) Details
IBI-939 IBI-939 Phase Ⅰ Innovent Biologics Cancer Details
COM-902 COM-902 Preclinical Compugen Cancer Details
BMS-986207 BMS-986207 Phase Ⅱ Bristol-Myers Squibb, Ono Pharmaceutical Solid tumours Details
BGB-A1217 BGB-A1217 Phase Ⅰ BeiGene Solid tumours Details
MK-7684 MK-7684 Phase Ⅱ Merck Sharp & Dohme Non small cell lung cancer (NSCLC) Details

This web search service is supported by Google Inc.